Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 19-Apr-24 6:00 PM View:  | Gillies Hunter Chief Medical Officer | Aerovate Therapeutics, Inc. (AVTE) | 17-Apr-24 | Option Exercise | 4,000 | $1.74 | $6,960.00 | 123% 3.25K to 7.25K | |
| 19-Apr-24 6:00 PM View: | Dake Benjamin T See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 17-Apr-24 | Planned Option Sale | 6,853 | $22.37 | $153,327.00 | (84%) 8.14K to 1.29K | |
| 19-Apr-24 6:00 PM View: | Dake Benjamin T See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 17-Apr-24 | Option Exercise | 6,853 | $2.14 | $14,665.40 | 531% 1.29K to 8.14K | |
| 19-Apr-24 6:00 PM View: | Gillies Hunter Chief Medical Officer | Aerovate Therapeutics, Inc. (AVTE) | 17-Apr-24 | Planned Option Sale | 4,000 | $22.38 | $89,521.80 | (55%) 7.25K to 3.25K | |
| 18-Apr-24 6:00 PM View: | Noyes Timothy P Chief Executive Officer Director | Aerovate Therapeutics, Inc. (AVTE) | 16-Apr-24 | Planned Option Sale | 10,000 | $24.70 | $246,971.00 | (100%) 10.0K to 0 | |
| 18-Apr-24 6:00 PM View: | Noyes Timothy P Chief Executive Officer Director | Aerovate Therapeutics, Inc. (AVTE) | 16-Apr-24 | Option Exercise | 10,000 | $2.14 | $21,400.00 | 100% 0 to 10.0K | |
| 12-Apr-24 6:00 PM View: | Eldridge George A See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 10-Apr-24 | Planned Option Sale | 7,500 | $26.85 | $201,392.00 | (79%) 9.46K to 1.96K | |
| 12-Apr-24 6:00 PM View: | Eldridge George A See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 10-Apr-24 | Option Exercise | 7,500 | $2.14 | $16,050.00 | 383% 1.96K to 9.46K | |
| 11-Apr-24 6:00 PM View: | Grayzel David S. Director | Aerovate Therapeutics, Inc. (AVTE) | 09-Apr-24 | Private Sale | 11,882 | $28.15 | $334,478.00 | (< 1%) 1.81M to 1.8M | |
| 03-Apr-24 6:00 PM View: | Noyes Timothy P Chief Executive Officer Director | Aerovate Therapeutics, Inc. (AVTE) | 01-Apr-24 | Planned Option Sale | 10,000 | $30.00 | $300,033.00 | (100%) 10.0K to 0 | |
| 03-Apr-24 6:00 PM View: | Eldridge George A See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 01-Apr-24 | Option Exercise | 12,495 | $2.14 | $26,739.30 | 638% 1.96K to 14.46K | |
| 03-Apr-24 6:00 PM View: | Verwijs Marinus CHIEF TECHNICAL OFFICER | Aerovate Therapeutics, Inc. (AVTE) | 01-Apr-24 | Option Exercise | 5,300 | $14.59 | $77,327.00 | 100% 0 to 5.3K | |
| 03-Apr-24 6:00 PM View: | Noyes Timothy P Chief Executive Officer Director | Aerovate Therapeutics, Inc. (AVTE) | 01-Apr-24 | Option Exercise | 10,000 | $2.14 | $21,400.00 | 100% 0 to 10.0K | |
| 03-Apr-24 6:00 PM View: | Dake Benjamin T See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 01-Apr-24 | Option Exercise | 3,325 | $10.61 | $35,278.20 | 258% 1.29K to 4.62K | (5%) |
| 03-Apr-24 6:00 PM View: | Verwijs Marinus CHIEF TECHNICAL OFFICER | Aerovate Therapeutics, Inc. (AVTE) | 01-Apr-24 | Planned Option Sale | 5,300 | $29.19 | $154,697.00 | (100%) 5.3K to 0 | |
| 03-Apr-24 6:00 PM View: | Dake Benjamin T See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 01-Apr-24 | Planned Private Option Sale | 3,325 | $31.97 | $106,317.00 | (72%) 4.62K to 1.29K | |
| 03-Apr-24 6:00 PM View: | Eldridge George A See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 01-Apr-24 | Planned Option Sale | 12,495 | $31.23 | $390,208.00 | (86%) 14.46K to 1.96K | |
| 01-Apr-24 6:00 PM View: | Gillies Hunter Chief Medical Officer | Aerovate Therapeutics, Inc. (AVTE) | 28-Mar-24 | Planned Option Sale | 9,000 | $29.50 | $265,500.00 | (73%) 12.25K to 3.25K | |
| 01-Apr-24 6:00 PM View: | Gillies Hunter Chief Medical Officer | Aerovate Therapeutics, Inc. (AVTE) | 28-Mar-24 | Option Exercise | 9,000 | $2.14 | $19,260.00 | 277% 3.25K to 12.25K | |
| 28-Mar-24 6:00 PM View: | Dake Benjamin T See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 27-Mar-24 | Option Exercise | 11,068 | $10.61 | $117,431.00 | 857% 1.29K to 12.36K | (5%) |
| 28-Mar-24 6:00 PM View: | Dake Benjamin T See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 27-Mar-24 | Planned Private Option Sale | 11,068 | $27.97 | $309,519.00 | (90%) 12.36K to 1.29K | |
| 27-Mar-24 6:00 PM View: | Dake Benjamin T See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 25-Mar-24 | Planned Private Option Sale | 3,432 | $28.01 | $96,119.30 | (73%) 4.72K to 1.29K | |
| 27-Mar-24 6:00 PM View: | Dake Benjamin T See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 25-Mar-24 | Option Exercise | 3,432 | $10.61 | $36,413.50 | 266% 1.29K to 4.72K | (5%) |
| 20-Mar-24 6:00 PM View: | Verwijs Marinus CHIEF TECHNICAL OFFICER | Aerovate Therapeutics, Inc. (AVTE) | 19-Mar-24 | Option Exercise | 5,300 | $14.59 | $77,327.00 | 100% 0 to 5.3K | |
| 20-Mar-24 6:00 PM View: | Verwijs Marinus CHIEF TECHNICAL OFFICER | Aerovate Therapeutics, Inc. (AVTE) | 19-Mar-24 | Planned Option Sale | 5,300 | $26.08 | $138,243.00 | (100%) 5.3K to 0 | |
| 20-Mar-24 6:00 PM View: | Gillies Hunter Chief Medical Officer | Aerovate Therapeutics, Inc. (AVTE) | 18-Mar-24 | Option Exercise | 7,000 | $1.91 | $13,380.00 | 215% 3.25K to 10.25K | |
| 20-Mar-24 6:00 PM View: | Dake Benjamin T See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 18-Mar-24 | Option Exercise | 35,057 | $5.64 | $197,837.00 | 2715% 1.29K to 36.35K | |
| 20-Mar-24 6:00 PM View: | Dake Benjamin T See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 18-Mar-24 | Planned Option Sale | 35,057 | $25.90 | $908,046.00 | (96%) 36.35K to 1.29K | |
| 20-Mar-24 6:00 PM View: | Gillies Hunter Chief Medical Officer | Aerovate Therapeutics, Inc. (AVTE) | 18-Mar-24 | Planned Option Sale | 7,000 | $25.87 | $181,057.00 | (68%) 10.25K to 3.25K | |
| 14-Mar-24 6:00 PM View: | Eldridge George A See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 13-Mar-24 | Option Exercise | 2,016 | $2.14 | $4,314.24 | 103% 1.96K to 3.98K | |
| 14-Mar-24 6:00 PM View: | Eldridge George A See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 13-Mar-24 | Planned Option Sale | 2,016 | $25.02 | $50,445.00 | (51%) 3.98K to 1.96K | |
| 14-Mar-24 6:00 PM View: | Eldridge George A See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 12-Mar-24 | Planned Option Sale | 2,051 | $25.05 | $51,369.60 | (51%) 4.01K to 1.96K | |
| 14-Mar-24 6:00 PM View: | Eldridge George A See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 12-Mar-24 | Option Exercise | 2,051 | $2.14 | $4,389.14 | 105% 1.96K to 4.01K | |
| 11-Mar-24 6:00 PM View: | Eldridge George A See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 11-Mar-24 | Planned Option Sale | 3,433 | $25.25 | $86,667.40 | (64%) 5.39K to 1.96K | |
| 11-Mar-24 6:00 PM View: | Eldridge George A See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 11-Mar-24 | Option Exercise | 3,433 | $2.14 | $7,346.62 | 175% 1.96K to 5.39K | |
| 11-Mar-24 6:00 PM View: | Eldridge George A See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 08-Mar-24 | Option Exercise | 114 | $2.14 | $243.96 | 6% 1.96K to 2.07K | |
| 11-Mar-24 6:00 PM View: | Eldridge George A See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 08-Mar-24 | Planned Option Sale | 114 | $25.00 | $2,850.00 | (5%) 2.07K to 1.96K | |
| 11-Mar-24 6:00 PM View: | Gillies Hunter Chief Medical Officer | Aerovate Therapeutics, Inc. (AVTE) | 07-Mar-24 | Planned Option Sale | 8,975 | $24.50 | $219,888.00 | (73%) 12.23K to 3.25K | |
| 11-Mar-24 6:00 PM View: | Eldridge George A See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 07-Mar-24 | Planned Option Sale | 22,386 | $25.00 | $559,688.00 | (92%) 24.35K to 1.96K | |
| 11-Mar-24 6:00 PM View: | Eldridge George A See Remarks | Aerovate Therapeutics, Inc. (AVTE) | 07-Mar-24 | Option Exercise | 22,386 | $2.14 | $47,906.00 | 1142% 1.96K to 24.35K | |
| 11-Mar-24 6:00 PM View: | Gillies Hunter Chief Medical Officer | Aerovate Therapeutics, Inc. (AVTE) | 07-Mar-24 | Option Exercise | 8,975 | $2.14 | $19,206.50 | 276% 3.25K to 12.23K | |
| 27-Feb-24 6:00 PM View: | Gillies Hunter Chief Medical Officer | Aerovate Therapeutics, Inc. (AVTE) | 23-Feb-24 | Option Exercise | 511 | $1.74 | $889.14 | 16% 3.25K to 3.76K | |
| 27-Feb-24 6:00 PM View: | Gillies Hunter Chief Medical Officer | Aerovate Therapeutics, Inc. (AVTE) | 23-Feb-24 | Planned Option Sale | 511 | $19.50 | $9,964.50 | (14%) 3.76K to 3.25K | |
| 22-Feb-24 6:00 PM View: | Gillies Hunter Chief Medical Officer | Aerovate Therapeutics, Inc. (AVTE) | 20-Feb-24 | Planned Option Sale | 3,489 | $20.23 | $70,574.50 | (52%) 6.74K to 3.25K | |
| 22-Feb-24 6:00 PM View: | Gillies Hunter Chief Medical Officer | Aerovate Therapeutics, Inc. (AVTE) | 20-Feb-24 | Option Exercise | 3,489 | $1.74 | $6,070.86 | 107% 3.25K to 6.74K | |
| 07-Feb-24 6:00 PM View: | Niven Ralph Chief Scientific Officer | Aerovate Therapeutics, Inc. (AVTE) | 05-Feb-24 | Option Exercise | 4,600 | $2.02 | $9,284.00 | 286% 1.61K to 6.21K | |
| 07-Feb-24 6:00 PM View: | Niven Ralph Chief Scientific Officer | Aerovate Therapeutics, Inc. (AVTE) | 05-Feb-24 | Planned Option Sale | 4,600 | $17.45 | $80,249.30 | (74%) 6.21K to 1.61K | |
| 19-Jan-24 6:00 PM View: | Gillies Hunter Chief Medical Officer | Aerovate Therapeutics, Inc. (AVTE) | 17-Jan-24 | Planned Option Sale | 4,000 | $19.50 | $78,000.00 | (55%) 7.25K to 3.25K | |
| 19-Jan-24 6:00 PM View: | Gillies Hunter Chief Medical Officer | Aerovate Therapeutics, Inc. (AVTE) | 17-Jan-24 | Option Exercise | 4,000 | $1.74 | $6,960.00 | 123% 3.25K to 7.25K | |
| 08-Jan-24 6:00 PM View: | Niven Ralph Chief Scientific Officer | Aerovate Therapeutics, Inc. (AVTE) | 05-Jan-24 | Option Exercise | 4,600 | $2.02 | $9,284.00 | 286% 1.61K to 6.21K |
